Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 45

1.

Structural basis for gate-DNA recognition and bending by type IIA topoisomerases.

Dong KC, Berger JM.

Nature. 2007 Dec 20;450(7173):1201-5.

PMID:
18097402
2.

Roles of nonhomologous end-joining pathways in surviving topoisomerase II-mediated DNA damage.

Malik M, Nitiss KC, Enriquez-Rios V, Nitiss JL.

Mol Cancer Ther. 2006 Jun;5(6):1405-14.

3.

Tyrosyl-DNA phosphodiesterase (Tdp1) participates in the repair of Top2-mediated DNA damage.

Nitiss KC, Malik M, He X, White SW, Nitiss JL.

Proc Natl Acad Sci U S A. 2006 Jun 13;103(24):8953-8. Epub 2006 Jun 2.

4.

Stability of the topoisomerase II closed clamp conformation may influence DNA-stimulated ATP hydrolysis.

Vaughn J, Huang S, Wessel I, Sorensen TK, Hsieh T, Jensen LH, Jensen PB, Sehested M, Nitiss JL.

J Biol Chem. 2005 Mar 25;280(12):11920-9. Epub 2005 Jan 12.

5.

A mutation in human topoisomerase II alpha whose expression is lethal in DNA repair-deficient yeast cells.

Walker JV, Nitiss KC, Jensen LH, Mayne C, Hu T, Jensen PB, Sehested M, Hsieh T, Nitiss JL.

J Biol Chem. 2004 Jun 18;279(25):25947-54. Epub 2004 Mar 22.

6.
7.

DNA topoisomerases in cancer chemotherapy: using enzymes to generate selective DNA damage.

Nitiss JL.

Curr Opin Investig Drugs. 2002 Oct;3(10):1512-6. Review.

PMID:
12431029
8.

DNA topoisomerase II as a target for cancer chemotherapy.

Walker JV, Nitiss JL.

Cancer Invest. 2002;20(4):570-89. Review. No abstract available.

PMID:
12094551
9.

Cellular roles of DNA topoisomerases: a molecular perspective.

Wang JC.

Nat Rev Mol Cell Biol. 2002 Jun;3(6):430-40. Review.

PMID:
12042765
10.

Tumor cell death induced by topoisomerase-targeting drugs.

Li TK, Liu LF.

Annu Rev Pharmacol Toxicol. 2001;41:53-77. Review.

PMID:
11264450
11.

Type II topoisomerases as targets for quinolone antibacterials: turning Dr. Jekyll into Mr. Hyde.

Anderson VE, Osheroff N.

Curr Pharm Des. 2001 Mar;7(5):337-53. Review.

PMID:
11254893
12.

Topoisomerase II-mediated cleavage of plasmid DNA.

Burden DA, Froelich-Ammon SJ, Osheroff N.

Methods Mol Biol. 2001;95:283-9. No abstract available.

PMID:
11089240
13.

Use of a real-time, coupled assay to measure the ATPase activity of DNA topoisomerase II.

Lindsley JE.

Methods Mol Biol. 2001;95:57-64. No abstract available.

PMID:
11089219
14.
15.

Molecular analysis of yeast and human type II topoisomerases. Enzyme-DNA and drug interactions.

Strumberg D, Nitiss JL, Dong J, Kohn KW, Pommier Y.

J Biol Chem. 1999 Oct 1;274(40):28246-55.

16.

Mutations of human topoisomerase II alpha affecting multidrug resistance and sensitivity.

Mao Y, Yu C, Hsieh TS, Nitiss JL, Liu AA, Wang H, Liu LF.

Biochemistry. 1999 Aug 17;38(33):10793-800.

PMID:
10451375
17.

Mutation of a conserved serine residue in a quinolone-resistant type II topoisomerase alters the enzyme-DNA and drug interactions.

Strumberg D, Nitiss JL, Rose A, Nicklaus MC, Pommier Y.

J Biol Chem. 1999 Mar 12;274(11):7292-301.

18.
19.

Moving one DNA double helix through another by a type II DNA topoisomerase: the story of a simple molecular machine.

Wang JC.

Q Rev Biophys. 1998 May;31(2):107-44. Review. No abstract available.

PMID:
9794033
20.

A mutant yeast topoisomerase II (top2G437S) with differential sensitivity to anticancer drugs in the presence and absence of ATP.

Sabourin M, Byl JA, Hannah SE, Nitiss JL, Osheroff N.

J Biol Chem. 1998 Oct 30;273(44):29086-92.

Supplemental Content

Support Center